VantroMarket Overview
← All markets
Health Market Overview

Poland

Last updated: November 2026
Regulatory Body
Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych (Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, URPL)
Typical Timeline
60-210 days
Regulatory Overview

The primary regulatory authority in Poland is the Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych (URPL), which operates under the supervision of the Minister of Health. The main governing legislation includes the Pharmaceutical Law Act of 2001 (as amended), the Medical Devices Act of 2022 (implementing EU MDR 2017/745 and IVDR 2017/746), and the Reimbursement Act of 2011. Pharmaceuticals may enter the Polish market via the centralized European Medicines Agency (EMA) procedure, the mutual recognition procedure (MRP), the decentralized procedure (DCP), or a national procedure administered directly by URPL. Medical devices and in vitro diagnostics follow EU conformity assessment pathways, with CE marking being the primary market access requirement, and must be registered in the Polish national medical device database (RPMK) before being placed on the market.

Applicants are required to appoint a local authorized representative or marketing authorization holder established within the European Economic Area. Pharmaceutical dossiers must conform to the Common Technical Document (CTD) format aligned with ICH guidelines, and submissions are accepted in English with Polish-language product information (Summary of Product Characteristics, labeling, and package leaflets) required for final approval. Key recent reforms include the full transposition of EU MDR and IVDR regulations, which significantly tightened conformity assessment requirements and post-market surveillance obligations for medical devices and diagnostics. Poland has also been modernizing its digital health regulatory framework, with the Ministry of Health developing guidance for Software as a Medical Device (SaMD) in line with MDCG guidance. The 2022 amendment to the Reimbursement Act introduced additional health technology assessment (HTA) requirements for market access, with the Agency for Health Technology Assessment and Tariff System (AOTMiT) playing a central role in reimbursement decisions.

Procurement Overview

Public procurement of health products in Poland is centralized primarily through the Ministry of Health and the National Health Fund (Narodowy Fundusz Zdrowia, NFZ), which is the single public payer responsible for financing and contracting healthcare services. Hospitals and healthcare institutions are largely publicly owned and funded through NFZ contracts, and they conduct their own tenders for medical supplies, devices, and pharmaceuticals in accordance with the Public Procurement Law (Prawo zamówień publicznych). Large-scale or strategically important procurements, such as those for vaccines, oncology medicines, and pandemic-related supplies, may be coordinated at the national level through the Ministry of Health or dedicated government agencies. Poland also participates in joint EU procurement mechanisms, particularly for vaccines and critical medical countermeasures, coordinated through the European Commission. The reimbursement and pricing framework for pharmaceuticals is governed by the Reimbursement Act, with reimbursement lists updated quarterly by the Minister of Health following HTA review by AOTMiT and price negotiations with manufacturers.

The private healthcare sector in Poland is substantial and growing, encompassing private hospitals, diagnostic laboratories, outpatient clinics, and pharmacy chains, which procure products independently through commercial channels and distributor agreements. Poland does not rely significantly on donor-funded procurement mechanisms such as those administered by UNICEF, the Global Fund, USAID, or Gavi, as it is a high-income EU member state with a domestically financed healthcare system. However, Poland has benefited from EU Structural Funds and the EU4Health program to co-finance health infrastructure investments, digitalization initiatives, and public health programs. Local manufacturing preference policies are not formally codified in procurement law, though there is increasing political interest in supporting domestic pharmaceutical and medical device production capacity, particularly following supply chain disruptions experienced during the COVID-19 pandemic. Tenderers must comply with EU public procurement directives as transposed into Polish law, ensuring open and competitive bidding processes for all publicly funded health product acquisitions.

Go deeper

This is a generic market overview. For a structured entry brief tailored to your product category, including regulatory pathway, pricing, and risk assessment, use the Market Brief tool.

Generate a free Market Brief for Poland →
Market overview generated by AI and updated monthly. Verify with in-country regulatory authorities before making market entry decisions.